Table 1.

Characteristics of the GOLDN study participants (n= 1092 at baseline).

Variable	Mean or Median1 ± SD or %
Age, years	48 ± 16
Sex, % female	51
Field center, % from Minnesota	51
High-sensitivity C-reactive protein, mg/dL
Baseline	0.12 ± 0.35
After fenofibrate treatment	0.12 ± 0.47
Interleukin-2 soluble receptor-α, pg/mL
Baseline	943 ± 361
After fenofibrate treatment	1039 ± 530
Interleukin-6, pg/mL
Baseline	1.40 ± 3.13
After fenofibrate treatment	1.47 ± 3.32
Tumor necrosis factor-α, pg/mL
Baseline	2.88 ± 5.21
After fenofibrate treatment	3.13 ± 4.06
Monocyte chemoattractant protein-1, pg/mL
Baseline	200 ± 16
After fenofibrate treatment	209 ± 75
Triglycerides, mg/dL
Baseline	141.65 ± 119.47
After fenofibrate treatment	90.78 ± 55.22
High density lipoprotein cholesterol, mg/dL
Baseline	47.20 ± 13.15
After fenofibrate treatment	49.47 ± 13.41
Low density lipoprotein cholesterol, mg/dL
Baseline	121.63 ± 31.46
After fenofibrate treatment	104.30 ± 31.30
Total cholesterol, mg/dL
Baseline	191.20 ± 38.97
After fenofibrate treatment	166.83 ± 34.37

¹Medians were used only for the inflammatory biomarkers due to skewness in the data.